44 results
8-K
RLAY
Relay Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s)) incident to the Company’s obligation to file such registration
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
Cancer Market Forecast report dated November 2023; 3. HR+/HER2- US late-line breast cancer patients compared to HR+/HER2- US incident breast cancer … patients; 4. FGFR2 altered late-line solid tumors compared to comprehensive annual FGFR2 altered incident solid tumors including additional FGFR gene
424B7
RLAY
Relay Therapeutics Inc
16 Nov 23
Prospectus with selling stockholder info
4:16pm
fees and expenses incident to the registration of the shares, but excluding brokerage commissions.
The selling stockholders, alternatively, may sell all
8-K
EX-99.2
fwbsx1 uc
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.2
2haasrb
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
593i0 rywnmxxydw6op
18 Apr 23
Regulation FD Disclosure
10:42am
8-K
EX-1.1
4sllrb qke6lo
15 Sep 22
Relay Therapeutics Announces Proposed Public Offering of Common Stock
6:33am
8-K
EX-99.2
qhkxyjfb wdp5grz
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am
424B7
33wfydlh ldggf
1 Sep 22
Prospectus with selling stockholder info
4:06pm
8-K
EX-99.2
p01gvh5qnhkj3 gt
27 Jun 22
Regulation FD Disclosure
6:11am